|Last Price||Today's Change||52-Week Range||Trading Volume|
|3.60 CAD||0.55 (+18.03%)||2.30 - 7.00||37.1 thousand (Above Avg)|
Market data as of 3:59PM 02/08/16. Quotes are delayed by at least 15 min.
Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis
Business Wire - Monday 02/08/2016 8:30 AM ET
Aurinia Pharmaceuticals to Attend Two Upcoming Investor Conferences
Business Wire - Thursday 02/04/2016 4:30 PM ET
Aurinia Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
Business Wire - Tuesday 02/02/2016 4:43 PM ET
Aurinia Pharmaceuticals to Present at the Canaccord Genuity Rare Disease and Bio-Pharma One on One Day
Business Wire - Friday 01/29/2016 6:53 PM ET
Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis
Business Wire - Tuesday 01/19/2016 5:17 PM ET
|Revenue Growth (1yr)||--|
|Net Income Growth (1yr)||--|
Data is delayed by at least 15 min.